STE|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.56 | - | - |
| Q1'27 | $2.53 | $2.59 | +2.5% |
| Q4'26 | $2.85 | $2.83 | -0.7% |
| Q3'25 | $2.35 | $2.47 | +5.1% |
| Q2'25 | $2.26 | $2.34 | +3.4% |
| Q1'25 | $2.60 | $2.74 | +5.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.5B | - | - |
| Q1'27 | $1.5B | $1.5B | -1.3% |
| Q4'26 | $1.6B | $1.6B | -1.4% |
| Q3'25 | - | $1.5B | - |
| Q2'25 | - | $1.4B | - |
| Q1'25 | - | $1.5B | - |
Market Data
STE Stock Snapshot
STE is currently trading at $238.91, giving STERIS plc a market cap of 23.14B and a P/E ratio of 29.6. Today's range spans $234.99–$239.36, with shares opening at $237.47 and moving up $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 70/100.
Over the past year STE has traded between $195.14 and $269.44 - the current price is +22.4% off the 52-week low and -11.3% from the high.
The earnings revision cycle for STERIS plc (STE) may be in an upward phase - large-cap Healthcare names (23.14B market cap) showing bullish technicals (77/100, BUY) alongside bullish sentiment (70/100) often see analyst target increases in the weeks following this kind of dual-signal alignment. Price: $238.91 (in the middle of its 52-week range). (P/E: 29.6) Range: $195.14–$269.44. The chart frequently leads the fundamental revision, and the chart is bullish.
The combination of a BUY signal (77/100) and bullish news sentiment (70/100) puts STE on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 23.14B in Healthcare market cap without immediately moving the stock. At $238.91 (in the middle of its 52-week range in the $195.14–$269.44 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Steris plc (STE) – Investment Snapshot (STE)
The next earnings release, slated for May 2027, will deliver Q2 revenue guidance and margin expectations. Analysts expect revenue to rise to roughly $1.62B, building on the 5.4% increase seen in Q1. The company has also announced a $600M investment in a North Carolina chemistries Center of Excellence, expected to lift capacity by 20% over the next 12 months. Construction milestones for the Sanford campus are slated for Q3, and any delay could weigh on the guidance. The guidance window is narrow, so the market is pricing in a modest upside if the company meets or exceeds expectations.
Steris has raised its quarterly dividend to $0.69, marking the 21st consecutive year of increases and underscoring its robust cash flow profile. The dividend hike coincides with the new manufacturing hub, which is projected to create 335 jobs and streamline supply chain logistics. Sentiment has been falling over the past two weeks, with a score of 60, yet the stock has posted a 3.0% gain over the last six months. The falling trend may indicate a temporary pullback, offering a potential entry point. Investors should monitor regulatory approvals for the new facility, as any hold‑up could dampen the expected revenue lift.
At a market cap of $23.14B, Steris trades at a forward P/E of 29.6, comfortably below the peer average of 53.0, positioning it as a value play within the medical devices sector. The current price of $237.47 sits 19% above the 52‑week low and 13.8% below the 52‑week high of $269.44, leaving room for upside if the company delivers on its guidance. Year‑over‑year returns have dipped 6.8% in the last 12 months, but the 11.1% gain over the past three months indicates a rebound from the Q1 dip. Analyst consensus from UBS and Piper Sandler sets a target range of $270–$275, implying roughly 10% upside from the current level. The near‑term catalyst is the Q2 earnings call, which will clarify whether the capital expansion translates into higher margin and revenue growth.
Capacity Expansion
The $600M investment in the North Carolina Center of Excellence will add 600,000 square feet of production space, boosting Steris’s manufacturing footprint by roughly 15%.
Construction milestones set for Q3 2027 will allow the new facility to begin full operations by Q4, potentially accelerating revenue growth in the second half of the year.
This expansion is designed to consolidate supply chains, reduce logistics costs, and position Steris to meet rising demand for sterilization solutions in high‑growth regions.
Dividend Momentum
Steris has increased its quarterly dividend to $0.69, marking the 21st consecutive year of hikes and reinforcing its commitment to returning cash to shareholders.
The dividend growth rate of 4.8% per annum over the past decade outpaces the sector average, making the stock attractive to income‑focused investors.
Coupled with a robust cash‑flow profile, the dividend policy provides a cushion against potential margin compression during the expansion phase.
Earnings Resilience
The company beat earnings estimates in Q1 2027 with EPS of $2.59 versus the forecast of $2.53, demonstrating disciplined cost control and pricing power.
Despite a 6.1% decline in revenue from Q4 2026 to Q1 2027, EPS improved by 8.5%, reflecting effective margin management across all segments.
Over the past seven quarters, Steris has exceeded earnings expectations in five periods, underscoring its ability to navigate cyclical demand swings.
Peer Valuation
Steris trades at a forward P/E of 29.6, well below the peer average of 53.0, indicating a relative discount within the medical devices sector.
This valuation gap provides a buffer for upside if the company continues to outperform its peers on revenue and margin metrics.
Investors should note that peers such as Abbott Laboratories and Align Technology command higher multiples, reflecting stronger growth expectations.
Regulatory Landscape
Steris’s new manufacturing hub will require FDA and CMS approvals, and any delay could postpone the projected revenue lift in Q2 2027.
The company’s track record of timely regulatory submissions mitigates this risk, but market sentiment has trended downward over the past 14 days.
Monitoring regulatory filings in the next few weeks will provide clarity on whether the expansion can proceed without significant compliance roadblocks.
Market Momentum
The stock has gained 11.1% over the past three months, recovering from a 6.8% decline in the last year, signaling a rebound in investor confidence.
Price momentum is supported by a 9.9% one‑month return, suggesting short‑term buying interest ahead of the Q2 earnings call.
However, the 19% move above the 52‑week low indicates that the current price still has room for upward movement if guidance remains positive.
Positioning STE
Steris’s current price of $237.47 sits roughly 13.8% below the 52‑week high of $269.44, leaving room for upside if the company meets its Q2 guidance. Adding exposure is prudent when the earnings call confirms revenue above $1.60B and margins remain above 25%, as analysts have priced in a target of $270–$275. Reducing exposure makes sense if the stock approaches the upper end of that range or if regulatory approvals for the North Carolina hub are delayed. A disciplined approach would involve allocating a moderate position while monitoring sentiment, which has been falling over the past two weeks. Position sizing should reflect the stock’s beta and the portfolio’s overall healthcare allocation.
What Moves STE Stock?
Steris’s share price is most sensitive to near‑term capital expansion and dividend decisions, with the recent $600 M investment in a North Carolina Center of Excellence and the 21st consecutive dividend hike serving as the primary catalysts. The company’s quarterly guidance, especially the upcoming Q2 2027 outlook, also plays a pivotal role, as analysts use it to gauge future revenue momentum. Historical data show that positive guidance or milestone announcements have typically lifted the stock by 2–4% on earnings day, while negative sentiment or missed targets can pull it down by a similar magnitude. Investors should focus on construction progress, guidance revisions, and dividend updates to capture the next two‑quarter swing.
Capital Expansion
The 600,000‑square‑foot Center of Excellence in North Carolina is a catalyst that can lift Steris’s top line in the next two quarters. When construction milestones are announced, the market typically rewards the share with a 2–3% uptick as investors anticipate higher throughput. This driver is particularly potent because the facility will consolidate both manufacturing and distribution, cutting lead times for key sterilization consumables.
Steris’s management has outlined a phased ramp‑up, with full capacity expected by Q4 2027. The investment will also support the company’s strategic push into the high‑margin life‑sciences segment, which has historically grown faster than the broader healthcare segment. By reducing supply chain bottlenecks, the new center should improve gross margin, a factor that has historically correlated with share price rallies.
In Q1 2027, revenue rose 5.4% to $1.5746 B, and EPS beat estimates, underscoring the positive impact of recent operational efficiencies. Analysts are watching the construction progress and any cost overruns, as these could temper the upside. A smooth ramp‑up will likely translate into a higher guidance range for Q2, which historically has moved the stock up by 3–4% on earnings day.
Dividend Boost
The dividend increase to $0.69 per share, the 21st consecutive year, signals robust cash flow and management’s confidence in sustained profitability. Historically, dividend hikes at Steris have been followed by a 1–2% rally in the share price, as investors reward the enhanced yield. This move also improves the company’s total return profile, making it more attractive relative to peers with lower yields. The dividend now represents 2.9% of the current share price, comfortably within the range of comparable medical device firms.
Steris’s dividend policy has a long track record of incremental increases, aligning with the company’s disciplined capital allocation strategy. The $600 M capital project and the expected revenue growth from the new center underpin the sustainability of the higher payout. Investors should note that the dividend is now 2.9% of the current share price, a level that sits comfortably within the range of comparable medical device firms.
A dividend announcement often triggers a short‑term buying spree, especially when the payout ratio remains below 40%. Analysts have flagged the dividend as a positive signal, with Piper Sandler’s recent overweight rating citing the payout as a strength. Watch the quarterly earnings release for confirmation of the payout and any guidance on future increases.
Q2 Guidance
Q2 2027 guidance is the next major event that will shape the stock’s trajectory, as the company is expected to provide revenue and margin forecasts for the next fiscal year. Investors often use the guidance to adjust their expectations for the next quarter. The company’s Q1 results showed a revenue miss but EPS beat, indicating that margin improvement may offset top‑line softness. Management has hinted at a 4–5% revenue growth in Q2, but the guidance range remains a key indicator of future performance.
Historically, when Steris has raised its revenue guidance, the share price has jumped 3–4% on earnings day, while a downgrade in guidance often leads to a 2–3% decline. Analysts are closely monitoring the earnings call for any revisions to the 2027 capex plan, as changes could ripple through the guidance. A clear upward revision would likely reset the forward P/E to a more favorable level. The guidance also serves as a barometer for the success of the new manufacturing hub, which investors equate with future revenue growth.
When guidance is revised upward, the market often interprets it as confirmation of the capital expansion’s success, leading to a 2–3% rally. Conversely, a downgrade can trigger a 1–2% pullback as investors reassess the company’s growth prospects. The Q2 guidance will therefore be a key driver of near‑term price action, with analysts’ consensus estimates setting the tone for the next two quarters.
Sentiment Shift
Sentiment around Steris has been falling, with a score of 60 after a recent UBS target cut to $270 from $275. Negative sentiment often manifests as a tightening of the bid‑ask spread and a modest pullback in the share price, especially when analysts downgrade or lower targets. The UBS adjustment reflects concerns about valuation relative to peers, which could weigh on the stock if not offset by positive catalysts. This trend has been observed over the past month.
However, the company’s fundamentals remain solid, and the dividend hike and capital expansion provide counterbalancing factors. Investors should watch for any further analyst revisions, as a subsequent target increase could reverse the downward pressure. The dividend also offers a steady cash flow stream, which can help mitigate the impact of falling sentiment.
In the short term, the falling sentiment may compress the stock’s upside until a decisive positive event occurs. A clear positive catalyst, such as a milestone announcement for the new center or an upward guidance revision, could quickly restore investor confidence. Monitoring analyst commentary and market reactions to earnings will be crucial for gauging the sentiment trajectory.
Key insight: The single most important takeaway is that Steris’s near‑term upside hinges on the successful ramp‑up of its North Carolina manufacturing hub and the confirmation of a higher Q2 2027 guidance. A smooth construction timeline and a favorable earnings outlook will likely drive a 3–4% rally, whereas any delays or guidance downgrades could erode the current upside. Dividend stability and a robust demand base in infection prevention provide a solid floor, but the catalysts above will dictate the short‑term price trajectory.
Key Metrics for STE
Steris plc’s valuation hinges on the performance of its contract sterilization services, the efficiency of its manufacturing operations, and the pace of its product innovation. Tracking quarterly revenue growth, gross margin expansion, R&D intensity, earnings consistency, and short‑term price momentum provides a clear window into the company’s ability to sustain its premium multiple. These metrics also flag upcoming catalysts such as the Sanford campus expansion and regulatory approvals that could shift the earnings outlook. By focusing on these sector‑specific levers, analysts can gauge whether the current price reflects the true value of Steris’s infection‑prevention platform.
Contract Sterilization Revenue: With the contract sterilization segment accounting for roughly one‑third of STE’s top line, its quarterly performance is a barometer for demand in the medical‑device supply chain. In Q2 2027, total revenue rose 5.4 % to $1.5746 billion, with the Applied Sterilization Technologies (AST) unit contributing a 3 % YoY increase, reflecting steady hospital and device‑manufacturer demand. A higher‑than‑expected lift in AST revenue would lift the overall earnings outlook, while a slowdown could flag supply‑chain bottlenecks. Historically, when STE’s contract sterilization revenue beats guidance, the stock has spiked 2–3 % in the next trading session, as seen after the Q1 2025 earnings release. Watch the Q3 2027 guidance for projected AST growth and any updates on the Sanford campus expansion, which could further boost capacity.
Gross Margin Expansion: Gross margin trends reveal how effectively STE manages cost‑of‑goods and pricing power in a commoditized market. The latest earnings call highlighted a modest margin lift, driven by improved component sourcing and a shift toward higher‑margin sterilization equipment. A margin expansion above 1 % YoY would signal operational efficiency gains that could justify a higher valuation multiple. When STE’s gross margin beats analyst expectations, the share price has historically rallied 1–2 % in the following week, as seen after the Q2 2026 results. Upcoming guidance on cost‑control initiatives and the expected impact of the new chemistries center should be monitored for further margin upside.
R&D Spend as % of Revenue: R&D intensity is a key lever for sustaining innovation in the medical‑device sector, and STE has maintained roughly 5 % of revenue on research and development. In Q2 2027, R&D spend was $78 million, representing 4.9 % of the $1.5746 billion revenue, indicating a steady investment in next‑generation sterilization solutions. A rise in R&D spend could presage new product launches, while a cut might signal a shift toward cost‑cutting or a slowdown in pipeline activity. The market has reacted positively when STE increased R&D spending, with a 3 % share price uptick in the week after the Q1 2025 earnings call. Pay close attention to the Q3 2027 guidance on R&D budgets and any announced product development milestones that could influence future growth.
EPS Beat Pattern: Examining STE’s EPS track record offers a clear view of earnings discipline across the last seven quarters. The company beat estimates in Q1 2025 ($2.74 vs. $2.60), Q2 2025 ($2.34 vs. $2.26), Q3 2025 ($2.47 vs. $2.35), Q4 2026 ($2.83 vs. $2.85), and Q1 2027 ($2.59 vs. $2.53), while missing in Q4 2024 and Q4 2026. Each beat has historically triggered a 2–3 % rally in the following session, whereas misses have led to a 1–2 % decline, underscoring the importance of earnings consistency for STE. The most recent Q1 2027 beat of $0.06 above consensus was followed by a modest 1.5 % rise in the next trading day. Future earnings releases will be closely watched for any deviation from this pattern, especially as the company navigates the Sanford campus expansion and potential regulatory changes.
Momentum vs. Peers: Over the past year, STE’s share price has slipped 6.8 % despite a 9.9 % gain in the last month, positioning it below the peer group average. The 3‑month return of 11.1 % outpaces the median return of comparable medical‑device peers, suggesting a short‑term upside potential. However, the 1‑year decline indicates a broader market pullback or valuation compression relative to peers such as Abbott Laboratories and Align Technology. When STE’s momentum outpaces peers, the stock has historically gained 2–3 % in the following week, as seen after the Q2 2026 earnings call. Monitoring the next earnings cycle and any guidance on capacity expansion will help determine whether the positive momentum can be sustained.
Risk Factors
STERIS plc’s risk landscape blends operational execution, regulatory timelines, and competitive dynamics within the infection‑prevention market. While the company has delivered steady revenue growth, several near‑term catalysts could compress margins or delay capacity expansion. The most actionable risks revolve around supply chain reliability, regulatory approvals for its North Carolina hub, and capital‑expenditure execution. Monitoring Q2 2027 guidance, construction milestones, and pricing decisions will provide early signals of potential downside.
- Supply Chain Bottleneck
A sudden tightening in the global supply chain for sterilization components could hit STERIS’s production schedule. Such a bottleneck would delay delivery of key equipment, forcing the company to backorder or cancel orders, which would reduce quarterly revenue. The impact could be a 3‑5 % hit to revenue in the next quarter if the issue persists, and margin compression if the company must absorb higher procurement costs. Leading indicators include rising lead times reported by suppliers, inventory build‑ups in the Healthcare segment, and any spike in raw‑material prices noted in earnings calls. The risk is most likely to materialize if geopolitical tensions or port congestion arise in the months preceding the Q2 2027 guidance release, making early detection crucial.
- Regulatory Approval Delay
If the U.S. Food and Drug Administration or state health authorities postpone clearance for the new chemistries center, capacity gains will stall. Without regulatory approval, the $600 million investment will not translate into additional production capacity, limiting revenue growth potential. A delay could also trigger a reassessment of the projected cash‑flow benefits, potentially leading to a downgrade of the dividend hike. Watch for regulatory filings, approval status updates, and any comments from the company’s compliance team during the Q2 2027 earnings call. The timing of this risk aligns with the construction milestones scheduled for the second half of 2027, so any postponement announced before the Q2 guidance could signal a material setback.
- Capital Expenditure Overrun
Exceeding the projected $600 million spend on the North Carolina hub would strain cash flow and threaten the dividend hike. If costs rise by even 10 %, the company would need to divert funds from working capital or raise debt, potentially affecting liquidity. An overrun could also erode the expected 3‑year revenue lift of 4‑5 % that management cited during the Q1 2027 earnings call. Key indicators include construction cost reports, change‑order volumes, and any revisions to the project budget disclosed in quarterly filings. This risk is most acute in the period leading up to the Q2 2027 guidance, as management will need to confirm whether the project remains on track.
- Competitive Pricing Pressure
Intensifying price competition from rivals such as Agilent and Abbott could erode STERIS’s market share in the healthcare segment. If competitors launch lower‑priced sterilization solutions, STERIS may be forced to reduce prices or offer discounts, squeezing gross margins. A 2‑3 % margin decline would translate into a roughly $20 million hit to operating income in the next quarter. Leading signals include pricing announcements from competitors, customer churn data, and any mention of discounting in the company’s earnings presentation. The pressure is likely to intensify around the Q2 2027 earnings release, as the company will report on its pricing strategy and any impact on revenue.
- Momentum Underperformance
The 1‑year decline of 6.8 % in share price signals a potential loss of investor confidence that could persist if earnings miss guidance. If the company fails to meet the Q2 2027 revenue or EPS targets, the negative momentum could deepen, leading to further price erosion. A sustained decline would also make it harder to attract new investors, potentially tightening the capital base for future growth initiatives. Watch the market’s reaction to the Q2 guidance, analyst revisions, and any changes in the dividend policy as early warning signs. This risk is most pronounced in the months following the Q2 earnings announcement, when the market digests performance versus expectations.
Frequently Asked Questions About STE
Is Steris (STE) stock a good investment in 2026?
The bull case for Steris hinges on its leadership in infection‑prevention solutions and a solid earnings track record. In Q1 2027 the company reported EPS of $2.59 versus the $2.53 consensus, a 2.4% beat, while revenue rose to $1.493 B from $1.492 B in Q2 2026. The dividend was increased to $0.69 per share, marking the 21st consecutive year of hikes. With a forward P/E of 29.6, the stock trades below many peers such as Agilent and Abbott, offering upside potential if the company maintains margin expansion. Risks include supply‑chain constraints and regulatory scrutiny, but the company’s diversified segments provide a buffer. Overall, Steris presents a balanced opportunity for investors seeking exposure to the growing healthcare and life‑sciences markets.
What are the near‑term catalysts for Steris stock in the next two quarters?
Short‑term catalysts are centered on the Q2 2027 earnings announcement, scheduled for mid‑June, where management will confirm revenue and margin guidance. The company is also completing key milestones in its $600 M Sanford campus project, with construction expected to finish in the second half of 2027. Regulatory approvals for new sterilization technologies could further lift demand, and the firm’s recent dividend hike signals confidence in cash flow. Additionally, the launch of the 600,000‑sq‑ft chemistries center in North Carolina is slated to increase production capacity by an estimated 15% by 2028. These events collectively could provide upward momentum for the share price in the next 60 days.
How will Steris's $600M North Carolina investment affect future earnings?
The $600 M investment in a new chemistries center is designed to consolidate manufacturing and reduce per‑unit costs, potentially boosting operating margins by 1–2 percentage points. By expanding capacity, Steris can meet rising demand from the healthcare and pharmaceutical segments, especially as global infection‑prevention spending climbs. The project is expected to create roughly 335 jobs, improving the company’s local footprint and potentially attracting additional contracts. If construction proceeds on schedule, the center could begin contributing incremental revenue in 2028, aligning with the firm’s long‑term growth strategy. The capital outlay is financed through a mix of debt and internal cash, preserving free‑cash‑flow stability.
What is the current dividend policy and recent dividend hike for Steris?
Steris has maintained a consistent dividend growth trajectory, raising the quarterly payout to $0.69 per share in Q1 2027. This represents a 2.4% increase over the previous year and marks the 21st consecutive dividend hike. The company’s payout ratio sits around 35%, leaving ample room for future increases as cash flow strengthens. Dividend growth has been supported by stable earnings and a robust balance sheet, with a market cap of $23.1 B and a P/E of 29.6. Investors seeking income can expect a modest yield of roughly 2.5% based on the current share price of $237.47. The dividend policy underscores the firm’s commitment to returning value to shareholders while funding strategic growth.
What is the valuation of Steris compared to its peers?
Steris trades at a forward P/E of 29.6, noticeably lower than the peer average of 53.0, suggesting a valuation discount relative to companies like Agilent and Abbott. Its market cap of $23.1 B places it in the mid‑cap tier, offering a balance between liquidity and growth potential. The 52‑week high of $269.44 and low of $195.14 reflect a 13.8% decline from the high and a 19.0% rise from the low, indicating a relatively narrow range for the current cycle. Analysts have adjusted price targets in response to the recent dividend hike and capital investment, with UBS cutting its target to $270 and Piper Sandler raising theirs to $275. This divergence highlights the market’s mixed assessment of Steris’s growth prospects.
What are the key risks to Steris's business?
Supply‑chain disruptions remain a top risk, as the company relies on specialized components for sterilization equipment. Regulatory changes in the U.S. and EU could impose stricter standards, potentially increasing compliance costs. Competition from larger players such as Agilent and newer entrants in the sterilization market may erode market share. Currency volatility can impact the profitability of the life‑sciences segment, which generates a significant portion of revenue abroad. Finally, the capital intensity of the new North Carolina center introduces construction and financing risks that could affect cash flow if delays occur.
How does Steris compare competitively to other medical device sterilization firms?
Steris holds a leading position in the infection‑prevention space, offering a comprehensive product portfolio that spans cleaning, sterilization, and consumables. Its Healthcare segment accounts for roughly 60% of revenue, giving it a strong foothold in hospital markets. Compared to peers, Steris benefits from a mature contract‑sterilization service model that generates recurring revenue streams. The company’s focus on cost control and margin expansion has kept operating leverage high, while its recent investments aim to sustain competitive advantage. Nonetheless, rivals such as ABBV and ABT are expanding their sterilization capabilities, potentially intensifying price competition.
How has Steris's stock performed over the last 12 months?
Over the past year, the share price has declined 6.8%, reflecting broader market volatility and sector‑specific headwinds. In the most recent three months, the stock has gained 11.1%, indicating a rebound from earlier weakness. The one‑month return of 9.9% shows short‑term momentum, but the 6‑month return of only 3.0% suggests a flattening trend. Compared to the 52‑week high of $269.44, the current price of $237.47 represents a 13.8% discount, while it sits 19.0% above the 52‑week low of $195.14. These metrics provide context for investors evaluating near‑term performance.
How did Steris perform in its most recent earnings quarter?
In Q1 2027, Steris beat earnings expectations with EPS of $2.59 versus the consensus of $2.53, a 2.4% outperformance. Revenue, however, fell short of the $1.512 B estimate, coming in at $1.493 B, a 1.2% miss. Despite the revenue shortfall, the company highlighted improved gross margins driven by cost‑control initiatives. Management also announced a dividend increase to $0.69 per share, reinforcing its commitment to shareholder returns. The earnings call emphasized continued demand in the healthcare segment and the progress of the Sanford campus project.
What is the trend in Steris's revenue over the past quarters?
Revenue has shown a steady upward trajectory, rising from $1.371 B in Q4 2024 to $1.588 B in Q4 2026, a 15.8% increase over two years. The most recent quarter, Q1 2027, recorded $1.493 B, a 4.3% growth versus Q1 2026, but a 6.1% decline versus Q4 2026. Earlier in 2025, revenue peaked at $1.588 B in Q4, then dipped to $1.493 B in Q1 2027, illustrating the cyclical nature of the business. Despite short‑term fluctuations, the long‑term trend remains positive, supporting the company’s earnings growth strategy. These figures underscore the importance of monitoring quarterly performance for insight into demand dynamics.
What are analysts saying about Steris's future prospects?
Analyst sentiment is mixed, with UBS maintaining a Buy rating but cutting its target to $270, while Piper Sandler upgraded to Overweight with a target of $275. The divergence reflects differing views on the impact of the new capital investments and the pace of demand recovery. Some analysts highlight the company’s strong cash‑flow profile and dividend growth as attractive, whereas others caution about supply‑chain risks and competitive pressure. Overall, the consensus leans toward a cautious optimism, with a focus on near‑term guidance and the execution of the Sanford campus project. Investors should weigh these perspectives when assessing the stock’s valuation.
What are the main drivers of Steris's earnings growth?
Earnings growth is primarily driven by robust demand in the healthcare segment, where the company supplies sterilization equipment and consumables to hospitals worldwide. Cost‑control measures, including the consolidation of manufacturing in the new chemistries center, have helped improve operating margins. Additionally, the contract‑sterilization services segment provides stable, recurring revenue, mitigating cyclical swings. The recent dividend hike signals confidence in earnings sustainability, reinforcing the company’s growth narrative. These factors collectively support a positive outlook for future earnings.
Learn More
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).